Cost cut needed to cover Friedreich's Ataxia drug - NCPE
There would have to be "significant price reduction" in the cost of a drug to treat Friedreich's Ataxia for it to be covered by the HSE, according to the National Centre for Pharmacoeconomics (NCPE).
We haven't written up this one. RTE News has the full story — the link below goes straight to it.